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Abstract
Introduction: Although osteoporosis has been reported to be more common in patients with rheumatoid arthritis
(RA), little is known whether the risk of osteoporotic fractures in these patients differs by age, sex, and anatomic
site.
Methods: A retrospective cohort study was conducted using a health care utilization database. Incidence rates (IRs)
and rate ratios (RRs) of osteoporotic fractures with 95% confidence intervals (CIs) were calculated. Multivariable Cox
proportional hazards models compared the risk of osteoporotic fracture at typical sites between RA and non-RA
patients.
Results: During a median 1.63-year follow-up, 872 (1.9%) of 47,034 RA patients experienced a fracture. The IR for
osteoporotic fracture at typical sites among RA patients was 9.6 per 1,000 person-years, 1.5 times higher than the
rate of non-RA patients. The IR was highest for hip fracture (3.4 per 1,000 person-years) in RA. The IRs across all age
groups were higher for women than men and increased with older age in both groups. The RRs were elevated in
RA patients across all common sites of osteoporotic fracture: hip (1.62, 95% CI 1.43 to 1.84), wrist (1.15, 95% CI 1.00
to 1.32), pelvis (2.02, 95% CI 1.77 to 2.30), and humerus (1.51, 95% CI 1.27 to 1.84). After confounding adjustment, a
modest increase in risk for fracture was noted with RA (hazard ratio 1.26, 95% CI 1.15 to 1.38).
Conclusions: Our study showed an increased risk of osteoporotic fractures for RA patients across all age groups,
sex and various anatomic sites, compared with non-RA patients.
Introduction
Rheumatoid arthritis (RA) is the most common form of
inflammatory arthritis in adults and is characterized by
chronic, progressive, systemic inflammation leading to
substantial pain, disability, and other morbidities [1-3].
It is well accepted that patients with RA are at an
increased risk of osteoporosis and osteoporotic fracture
[4-11], even though a previous US population-based
study based on the data from the Third National Health
and Nutrition Examination Survey (1988 to 1994) did
not find a difference in femoral neck bone mineral den-
sity (BMD) between RA and non-RA patients [12].
Osteoporosis, particularly in patients with RA, is a mul-
tifactorial condition. Some studies have suggested the
association between osteoporosis and proinflammatory
cytokines such as TNF-a,I L - 1a n dI L - 6 ,a st h e s ec y t o k i n e s
play an important role in bone resorption [13-19]. Positive
correlations between osteoporosis and C-reactive protein
(CRP), a marker of active inflammation, have been
observed, although not always confirmed, in a number of
epidemiologic studies [16,17,20-22]. Other known risk fac-
tors for osteoporosis include older age, female sex, meno-
pause, lower body mass index, glucocorticoids use, high
RA disease activity, long RA disease duration, and
decreased physical activity [8,9,19,22-27]. Osteoporotic
fracture, particularly at the hips, is associated with the risk
of falling [28,29]. Fall-related risk factors such as impaired
heel-toe walking and inability to do stand-ups without
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non-RA patients [24], probably related to impaired balance
and poor lower limb muscle strength. In addition, RA
patients have chronic polyarticular pain, which increases a
risk of falls [31]. A high prevalence of osteoporosis is
observed as 50% of 925 female RA patients in a large Ita-
lian multicenter cross-sectional study had osteoporosis
defined as BMD T-score lower than -2.5 in at least one
region of measurement, although it might have been over-
estimated due to referral bias [23].
Although an increased risk of osteoporosis in RA
patients is well-reported, little information is available
with regard to the population-based frequency of inci-
dent osteoporotic fractures in RA patients and their risks
relative to different age groups, sex, anatomic site, and
glucocorticoid use. We studied a very large cohort from a
health care utilization database: to estimate the incidence
rate (IR) of typical osteoporotic fractures among RA
patients relative to age, sex an da n a t o m i cs i t e ;t oa s s e s s
the risk of typical osteoporotic fractures among RA com-
pared with non-RA patients; and to evaluate the effects
of rheumatoid factor (RF) and acute phase reactants on
fracture risk among patients with RA.
Materials and methods
Data source
We conducted a cohort study using the administrative
claims data in the HealthCore Integrated Research Data-
base (HIRD) for the period 1 January, 2001 to 30 June,
2008. This database contained longitudinal claims infor-
mation including medical diagnoses, procedures, hospi-
talizations, physician visits, and pharmacy dispensings
on more than 28 million fully-insured subscribers, with
medical and pharmacy coverage, to 14 Blue Cross/Blue
Shield health plans across the USA. Results for outpati-
ent laboratory tests, including CRP, erythrocyte sedi-
mentation rate (ESR), and RF were available on a subset
of beneficiaries. No information was available on the
results of BMD tests or on other radiologic procedures.
Personal identifiers were removed from the dataset
before the analysis to protect subject confidentiality.
Patient informed consent was, therefore, not required.
This study was approved by Brigham and Women’s
Hospital’s Institutional Review Board and Data Use
Agreements were in place with HealthCore, Inc.
Study cohort
Adults aged 18 years or older with at least two visits for
RA identified with the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD 9-
CM) code, 714.xx, were eligible for this study. Subjects
who did not have a diagnosis of RA at any time during
the entire study period were eligible to be part of the
non-RA cohort. From this eligible non-RA cohort, five
patients, matched on age and sex were selected for
every subject with RA. The follow-up period began at
the index date, defined as the date of second RA diagno-
sis for RA patients and the date of the first medical
claim for the non-RA patients. We further required all
subjects to have at least 12 months of continuous health
plan eligibility before the start of follow-up. Subjects
were then followed until occurrence of outcomes, loss
of eligibility, end of study database, or death.
Outcome definitions
The definitions of fracture were based on diagnoses and
procedure codes contained within the study database [see
Additional file 1]. We included hip, wrist, humerus, and
pelvis fractures, because these are considered to be typical
sites of osteoporotic fracture and can be accurately defined
in administrative claims databases [32]. A composite of
fractures at these four sites (‘any osteoporotic fracture’)
was also considered. Patients were censored at their first
fracture in the ‘any osteoporotic fracture’ analysis.
Covariates
Variables potentially related to a future fracture were
assessed using the data from the 12 months prior to the
index date. These variables included demographic fac-
tors (age and sex), osteoporosis-related factors (osteo-
porosis diagnosis, osteoporosis medications, prior
fracture, BMD test, Parkinson’s disease, Alzheimer’s dis-
ease, prior falls, and other comorbidities), use of other
medications likely to be associated with bone metabo-
lism or fall risks (oral glucocorticoids, anticonvulsants,
benzodiazepines, selective serotonin reuptake inhibitors
(SSRIs), beta blockers, proton pump inhibitors, and
opioids), and health care utilization factors (number of
physician visits, acute care hospitalizations, and number
of different medications). To quantify patients’ comor-
bidities, we calculated the Deyo-adapted Charlson
comorbidity index based on ICD-9-CM [33,34]. The
comorbidity index is a summative score, based on 19
major medical conditions including myocardial infarc-
tion, pulmonary disease, renal disease, hepatic disease,
diabetes, cancer, HIV infection, etc. A score of 0 repre-
sents absence of comorbidity and a higher score indi-
cates a greater number of comorbid conditions.
To explore a potential association between the disease
status and fracture risk in patients with RA, we calcu-
lated the Claims-based Index for RA Severity (CIRAS)
scores [35], based on age, sex, number of tests for
inflammatory markers, number of chemistry panels and
platelet counts ordered, RF, the number of rehabilitation
and rheumatology visits, and Felty’s syndrome diagnosis,
and examined outpatient laboratory data such as acute
phase reactants (i.e., ESR or CRP) and RF levels in a
subgroup of the RA cohort.
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We compared the baseline characteristics between the
RA and non-RA cohorts. Fracture IRs with 95% confi-
dence intervals (CI) were calculated for all patients, and
then stratified by age and sex. Rate ratios (RRs) were esti-
mated by dividing the IR among RA patients by the IR
among non-RA [36]. Similar analyses were carried out
for specific anatomic site fractures, and then stratified by
baseline oral glucocorticoid use. Finally, to adjust for
potential confounders, separate Cox proportional hazard
models were used to compare the risks for any fracture
and fracture at each site among RA patients with those
in non-RA patients. Additional Cox proportional hazard
models focused on the risks relative to age and sex.
Finally, we conducted subgroup analyses to examine
whether positive RF and elevated acute phase reactants,
either ESR or CRP, increased a risk of fracture in RA
patients. All analyses were performed using SAS 9.1
Statistical Software (SAS Institute Inc., Cary, NC, USA).
Results
Cohort selection
There were more than 28.7 million potentially eligible
subjects in the study database. Figure 1 displays our
cohort selection process. There were initially 167,161
subjects with at least one RA diagnosis and approxi-
mately 28.5 million subjects with no RA diagnosis at
any time during the entire study period. Subsequently,
93,328 patients with at least one RA diagnosis, repre-
senting 0.32% of the potentially eligible population, and
9.2 million subjects with no RA diagnosis at any time
during the study period met our eligibility criteria. We
then matched 92,827 RA patients to 921,715 non-RA
subjects by age, sex, plan type, calendar year, and state
with a 1:10 ratio. After requiring a minimum of 12-
months of eligibility prior to two physician visits for RA,
the number of RA patients dropped to 47,034. Our final
study cohort includes 47,034 RA patients and 235,170
non-RA patients matched on age and sex with a 1:5
ratio. The median follow-up time was 1.63 years for RA
patients and 1.64 years for non-RA patients, accounting
for 91,315 person-years in RA subjects and 488,929
person-years in non-RA patients.
Patient characteristics
Baseline characteristics of the age- and sex-matched
c o h o r t sw e r ec o m p a r e d( T a b l e1 ) .T h em e d i a na g ew a s
55 years and 73% were women in both cohorts. Sub-
stantial differences across almost all other baseline char-
acteristics were observed between the cohorts, with the
prevalence of fracture risk factors much more common
in RA patients than non-RA subjects. A recorded diag-
nosis of osteoporosis, comorbidity, oral glucocorticoid
use, and health care utilization including physician visits
Figure 1 Selection of the study cohort. d, days; HIRD, HealthCore Integrated Research Database; RA, rheumatoid arthritis.
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patients with RA.
Incidence rates of any fracture
During the study follow-up, 3,968 patients (1.4%) of the
study population experienced a fracture. As shown in
Table 2, the IR of fracture at any of the four sites (wrist,
humerus, hip, and pelvis) among RA patients was 9.6
per 1,000 person-years and 1.5 times higher than that of
non-RA patients (6.3 per 1,000 person-years). The RRs
of experiencing any osteoporotic fractures among RA
patients compared with non-RA ranged from 1.35
(above age 85 years) to 2.13 (age between 65 and
74 years). Similar age trends were observed in the stratified
analyses by sex.
Incidence rates of fracture by anatomic sites
Site-specific fracture IRs were calculated for hip, wrist,
humerus, and pelvis (Table 3). Among the RA patients,
humerus fracture had the lowest IR (1.6 per 1,000 per-
son-years) and hip fracture the highest (3.4 per 1,000
person-years). The IR for humerus fracture was also
lowest (1.0 per 1,000 person-years) among non-RA
patients, but the IR for wrist fracture was the highest
(2.2 per 1,000 person-years). Among women with RA,
the highest IR was noted for pelvis fracture (4.0 per
1,000 person-years). The fracture IR at hip was 3.8 per
1,000 person-years. In male RA patients, the fracture IR
was 2.4 per 1,000 person-years at hip and 1.5 per 1,000
person-years at pelvis. The RRs were elevated across all
anatomic sites for both men and women, ranging from
1.12 to 2.05, except those for wrist fracture for both
men and women, and humerus fracture for men.
Adjusted risks of fracture among patients with RA
All the variables listed in Table 1 were adjusted by fit-
ting multivariable Cox proportional hazards models.
The adjusted hazard ratio (HR) for any fracture was
1.26 (95% CI 1.15 to 1.38) in RA patients compared
w i t hn o n - R A .A g e ,f e m a l es e x ,o s t e o p o r o s i sd r u g s ,
SSRIs, anticonvulsants, and opioids, history of Parkin-
son’s disease, prior fall and fracture, and hospitalization,
numbers of physician visits and prescription drugs, and
the comorbidity index were independently associated
with an increased risk of fracture [see Additional file 2].
Prior use of oral glucocorticoids also increased a risk of
osteoporotic fracture (HR 1.15, 95% CI 1.03 to 1.27).
Furthermore, the adjusted HRs were consistently ele-
vated in RA patients across all age and sex groups
(Figure 2). Additional multivariable Cox regression ana-
lyses (Figure 3) showed increased HRs associated with
RA for fractures at the hip (1.44, 95% CI 1.24 to 1.67)
and pelvis (1.41, 95% CI 1.20 to 1.66), but not for
humerus (1.26, 95% CI 1.00 to 1.58) or wrist fractures
(1.03, 95% CI 0.86 to 1.23).
Subgroup analyses on laboratory data
Subgroup analyses examined the effect of RF (n = 7,016,
15%) and acute phase reactants (n = 10,309, 22%) on
fracture risk among the RA patients with these labora-
tory data available. Positive RF (adjusted HR, 1.39, 95%
CI 0.78 to 2.49) and elevated acute phase reactants
(adjusted HR 1.30, 95% CI 0.85 to 1.99) were associated,
although not statistically significant, with an increased
fracture risk among the patients with RA after multivari-
able adjustment in Cox models. Prior use of oral gluco-
corticoids also increased risk of osteoporotic fracture
among the patients in this subgroup analysis (adjusted
HR 1.36, 95% CI 0.86 to 2.14).
Table 1 Baseline characteristics of the study cohort
12 months prior to the index date
RA patients
(n = 47,034)
Non-RA
patients
§
(n = 235,170)
Demographic
Age, years 55 (46-64) 55 (46-64)
Sex, female 34,169 (73) 170,845 (73)
Osteoporosis-related
Osteoporosis diagnosis 8,385 (18) 16,724 (7)
Osteoporosis medication 5,634 (12) 14,067 (6)
Prior fracture 413 (0.9) 1,322 (0.6)
Bone mineral density test 5,802 (12) 13,307 (6)
Parkinson’s disease 177 (0.4) 718 (0.3)
Alzheimer’s disease 156 (0.3) 752 (0.3)
Prior fall 609 (1) 2351 (1)
At least one comorbidity 39,259 (83) 53,299 (23)
Comorbidity index * 1 (1-2) 0 (0-0)
CIRAS score 5.2 (3.7-6.9) 3.6 (2.9-4.3)
Medication use
Oral glucocorticoids 18,222 (39) 15,342 (7)
Anticonvulsants 3,703 (8) 7,795 (3)
Benzodiazepines 8,362 (18) 25,754 (11)
SSRIs 7,289 (16) 22,920 (10)
Beta-blockers 6,520 (14) 25,166 (11)
Proton pump inhibitors 9,415 (20) 19,859 (8)
Opioids 22,049 (47) 54,204 (23)
Health care utilization
Number of physician visits 8 (5-14) 2 (0-6)
Hospitalizations 8,894 (19) 25,131(11)
Number of all prescription drugs 8 (4-13) 3 (0-7)
Data are expressed as number (%) or median (interquartile range);
§ 1:5
matched on age and sex. *, Charlson-Deyo Comorbidity Index [33]; a score of
0 represents absence of comorbidity and higher scores indicate a greater
burden of comorbidity.
CIRAS, Claims-based Index for RA Severity; RA, rheumatoid arthritis; SSRI,
selective serotonin reuptake inhibitor.
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Osteoporotic fractures are more common in patients
with RA than the general population. We studied the IRs
of osteoporotic fracture of the humerus, wrist, hip, and
pelvis in a cohort of 47,034 RA patients using claims
data. The IRs of fracture were 1.5 times higher among
patients with RA compared with non-RA patients regard-
less of age, sex, or anatomic sites. This association
between RA and fracture weakened after multivariable
adjustment for known risk factors of osteoporosis includ-
ing oral glucocorticoid use.
Chronic inflammation has been recently recognized as
a potential risk factor for osteoporosis and fracture [14].
T h eH e a l t hA g i n ga n dB o d yC o m p o s i t i o nS t u d ys h o w e d
that elevated inflammatory markers, such as IL-2, IL-6,
CRP, and TNF-a, were associated with osteoporotic frac-
ture [18]. In a study of 74 post-menopausal women with
RA, high disease activity, measured by high CRP levels
and ESR, and an elevated IL-6 were associated with an
increase in periarticular as well as systemic bone resorp-
tion [19]. We performed subgroup analyses adjusted for
either RF or acute phase reactants, in which the activity
Table 2 Incidence rates of any osteoporotic fractures* for study population, by age and sex
Age (years) RA patients Non-RA patients
§
Fractures, N Person-years IR
(95% CI)
Fractures, N Person-years IR
(95% CI)
RR
† (95% CI)
All
All ages 872 91,315 9.6
(8.9-10.2)
3,096 488,929 6.3
(6.1-6.6)
1.51
(1.40-1.63)
< 50 92 31,458 2.9
(2.3-3.5)
285 164,629 1.7
(1.5-1.9)
1.69
(1.34-2.14)
50-64 225 39,376 5.7
(5.0-6.5)
769 203,945 3.8
(3.5-4.0)
1.51
(1.30-1.75)
65-74 186 11,278 16.5
(14.1-18.9)
504 65,018 7.8
(7.1-8.4)
2.13
(1.80-2.52)
75-84 236 7,043 33.5
(29.2-37.8)
900 41,385 21.8
(20.3-23.2)
1.54
(1.33-1.78)
85+ 133 2,160 61.6
(51.1-72.1)
638 13,952 45.7
(42.2-49.3)
1.35
(1.12-1.63)
Women
All ages 742 66,785 11.1
(10.3-11.9)
2,653 355,094 7.5
(7.2-7.8)
1.49
(1.37-1.62)
< 50 73 23,267 3.1
(2.4-3.9)
197 121,361 1.6
(1.4-1.9)
1.94
(1.48-2.54)
50-64 180 28,631 6.3
(5.4-7.2)
652 145,980 4.5
(4.1-4.8)
1.41
(1.20-1.66)
65-74 166 8,006 20.7
(17.6-24)
436 45,729 9.5
(8.6-10.4)
2.18
(1.82-2.61)
75-84 204 5,153 39.6
(34.2-45)
780 30,532 25.6
(23.8-27.3)
1.55
(1.33-1.81)
85+ 119 1,768 67.3
(55.2-79.4)
588 11,492 51.2
(47.0-55.3)
1.32
(1.08-1.61)
Men
All ages 130 24,530 5.3
(4.4-6.2)
443 133,835 3.3
(3.0-3.6)
1.60
(1.32-1.95)
< 50 19 8,231 2.3
(1.3-3.4)
88 43,268 2.0
(1.6-2.5)
1.14
(0.69-1.87)
50-64 45 10,745 4.2
(3.0-5.4)
117 57,965 2.0
(1.7-2.4)
2.07
(1.47-2.92)
65-74 20 3,272 6.1
(3.4-8.8)
68 19,289 3.5
(2.7-4.4)
1.73
(1.05-2.85)
75-84 32 1,890 16.9
(11.1-22.8)
120 10,853 11.1
(9.1-13.0)
1.53
(1.04-2.26)
85+ 14 392 35.8
(17.0-54.5)
50 2,460 20.3
(14.7-26.0)
1.76
(0.97-3.18)
Rates are shown per 1,000 person-years.
§, 1:5 matched on age and sex; *, includes incident fractures of hip, wrist, pelvis, or humerus;
†, unadjusted. CI, confidence interval; IR, incidence rates;. RR, rate
ratio.
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taken into consideration. Both RF positivity and elevated
acute phase reactant levels increased the risk of fracture
but the association was not statistically significant. The
association between oral glucocorticoid use and fracture
risk remained increased among the subgroup of RA
p a t i e n t si nw h o mt h e s el a b o r a t o r yd a t aw e r ea v a i l a b l e .
Nonetheless, our subgroup analyses might not have suffi-
cient power to assess the independent association
between these potential risk factors (i.e., RF, acute phase
reactants, oral glucocorticoid use, and other medications)
and fracture risks.
The recently developed World Health Organization
fracture risk assessment tool, FRAX®, computes the 10-
year probability of hip fracture or a major osteoporotic
fracture, based on individual patient models that inte-
grate the risks associated with BMD at the femoral neck
as well as clinical risk factors such as age, sex, smoking
status, use of glucocorticoids, history of osteoporosis
and prior fall, and RA [37]. Fracture risk related to RA
independent of BMD (RR 1.73, 95% CI 0.94 to 3.20)
incorporated in this tool is higher than our results (HR
1.26, 95% CI 1.15 to 1.38) [38]. This difference is prob-
ably associated with baseline characteristics of study
population and degree of confounding adjustment.
Several strengths of this study are worth noting. We
examined a very large cohort of RA and non-RA
patients in a population that is representative of the US
commercially-insured population. Our multivariable Cox
models were simultaneously adjusted for more than 20
risk factors of osteoporotic fracture. Various subgroup
analyses enabled us to provide specific risks relative to
age, sex, anatomic site, and laboratory results. Our
results are consistent with a population-based study of
30,262 RA patients in the UK [9]. The authors noted
that patients with RA had an increased risk of fracture
Table 3 Incidence rates of fractures for study population, by anatomic site and sex
Anatomic site RA patients Non-RA patients
§
Fractures, n Person-years IR
(95% CI)
Fractures, n Person-years IR
(95% CI)
RR
†
(95% CI)
All
Wrist 234 92,167 2.5
(2.2-2.9)
1,088 492,138 2.2
(2.1-2.3)
1.15
(1.0-1.32)
Humerus 143 92,326 1.6
(1.3-1.8)
498 493,117 1.0
(0.9-1.1)
1.53
(1.27-1.84)
Hip 311 92,161 3.4
(3-3.7)
1,027 492,569 2.1
(2-2.2)
1.62
(1.43-1.84)
Pelvis 304 92,100 3.3
(2.9-5.7)
804 492,735 1.6
(1.5-1.7)
2.02
(1.77-2.30)
Any site 872 91,314 9.6
(8.9-10.2)
3,096 488,929 6.3
(6.1-6.6)
1.51
(1.40-1.63)
Women
Wrist 197 67,533 2.9
(2.5-3.3)
933 357,899 2.6
(2.4-2.8)
1.12
(0.96-1.31)
Humerus 130 67,646 1.9
(1.6-2.3)
432 358,719 1.2
(1.1-1.3)
1.60
(1.32-1.95)
Hip 253 67,535 3.8
(3.3-4.2)
873 358,252 2.4
(2.3-2.6)
1.54
(1.34-1.77)
Pelvis 267 67,449 4.0
(3.5-4.4)
700 358,388 2.0
(1.8-2.1)
2.03
(1.76-2.34)
Any site 742 66,785 11.1
(10.3-11.9)
2,653 355,094 7.5
(7.2-7.8)
1.49
(1.37-1.62)
Men
Wrist 37 24,634 1.5
(1.0-2.0)
155 134,239 1.2
(1.0-1.3)
1.30
(0.91-1.86)
Humerus 13 24,680 0.5
(0.2-0.8)
66 134,398 0.5
(0.4-0.6)
1.08
(0.60-1.96)
Hip 58 24,626 2.4
(1.8-3.0)
154 134,317 1.2
(1.0-1.3)
2.05
(1.52-2.77)
Pelvis 37 24,651 1.5
(1.0-2.0)
104 134,346 0.8
(0.6-0.9)
1.95
(1.34-2.84)
Any site 130 24,530 5.3
(4.4-6.2)
443 133,835 3.3
(3.0-3.6)
1.60
(1.32-1.95)
Rates are shown per 1,000 person-years.
†, unadjusted.
§, 1:5 matched on age and sex. CI, confidence interval; IR, incidence rates;. RR, rate ratio.
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to 1.6). Similar to our findings, the RR of fracture was
highest for hip fracture and lowest for wrist.
There are, however, limitations to our study. First, this
cohort study is likely to be subject to residual confound-
ing by race, body mass index, calcium and vitamin D
intake, frailty, and other unmeasured risk factors.
Although we assessed variables potentially related to a
future fracture using the data from the 12 months prior
to the index date, this time period might not be long
enough to capture all the information on potential con-
founders. We used both the comorbidity index and
CIRAS scores to minimize the effect of such confoun-
ders. The comorbidity index has been widely used to
measure comorbidity in various medical fields since its
development [33,39-41]. Previous research showed mod-
erate correlations between the CIRAS and a previously
validated medical records-based index of severity [35].
The substantial change in point estimates after multi-
variable adjustment indicates that further improved
adjustment may explain our findings. We also con-
ducted additional analyses on a subgroup of RA
patients, in whom laboratory data were available, to
assess whether the severity of RA affects the risk of frac-
ture, and observed an increased risk associated with
positive RF and elevated acute phase reactants, although
it was not statistically significant. The analyses of labora-
tory test results need to be interpreted with caution as
ordering laboratory tests in clinical practice is not a ran-
dom process but often related to the disease status. Sec-
ond, there could be misclassification with the diagnoses
of RA and osteoporotic fractures as we mainly relied on
Figure 2 Adjusted hazard ratios with 95% confidence intervals
for fractures among RA patients compared with non-RA
patients, by age and sex. Simultaneously adjusted for age, sex,
medications including oral glucocorticoids, osteoporosis drugs, beta
blockers, opioids, anticonvulsants, proton pump inhibitors, and
selective serotonin reuptake inhibitors, Parkinson’s disease,
Alzheimer’s disease, prior fall, prior fracture, history of bone mineral
density test, comorbidity index, Claims-based Index for RA Severity
score, and other health care utilization characteristics.
Figure 3 Adjusted hazard ratios with 95% confidence intervals
for fracture among RA patients compared with non-RA
patients by anatomic site. Simultaneously adjusted for age, sex,
medications including oral glucocorticoids, osteoporosis drugs, beta
blockers, opioids, anticonvulsants, proton pump inhibitors, and
selective serotonin reuptake inhibitors, Parkinson’s disease,
Alzheimer’s disease, prior fall, prior fracture, history of bone mineral
density test, comorbidity index, Claims-based Index for RA Severity
score, and other health care utilization characteristics.
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Page 7 of 10diagnosis and procedure codes to identify them. Both
the ICD codes for RA and the ICD codes and/or proce-
dure codes for fractures have been used in a number of
studies [32,42-45]. Third, we relied on prescription dis-
pensing records in the database to determine patients’
drug exposures including oral glucocorticoids. It may
not be the most accurate way to verify individuals’ daily
drug exposures, but it is still considered as one of the
best ways to ascertain drug exposure status in non-
experimental settings [46].
Finally, as true in most epidemiologic studies, patients
were not randomly exposed to drugs in our study.
Therefore, we cannot exclude the possibility of con-
founding by indication with regard to the effect of glu-
cocorticoids on fracture risk in patients with RA. The
detrimental effect of glucocorticoids on fracture might
have been confounded if the drug was selectively given
to patients with a higher degree of systemic inflamma-
tion and RA severity, and if the degree of systemic
inflammation and the severity of RA correlated with the
risk of fracture. Several studies recently reported a
potentially beneficial effect of low-dose, short-term sys-
temic glucocorticoids on BMD in RA due to its anti-
inflammatory effects [25,47-49]. Although this study was
not designed to address a potential role of disease-modi-
fying anti-rheumatic drugs including TNF-a inhibitors
in the risk of osteoporotic fracture among RA patients,
there is some evidence suggesting a beneficial effect of
such drugs on bone loss [15,48,50]. The exact effects of
glucocorticoids or disease-modifying anti-rheumatic
drugs on the risk of fractures in RA should be further
studied.
Conclusions
Our study found that patients with RA are at an
increased risk of osteoporotic fractures across age
groups, sex and various anatomic sites. An independent
association between the use of oral glucocorticoids and
fracture risk was confirmed. Future research that evalu-
ates the effect of RA treatments on the risk of osteo-
porosis would be important.
Additional material
Additional file 1: Definition of fracture outcomes. A list of diagnosis
and procedure codes to define fracture outcomes.
Additional file 2: Adjusted hazard ratios with 95% confidence
intervals for any osteoporotic fractures. Adjusted hazard ratios (HR)
with 95% confidence intervals (CI) for any osteoporotic fracture from a
multivariable Cox proportional hazards model.
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